Cargando…

rAAVrh74.MCK.GALGT2 Demonstrates Safety and Widespread Muscle Glycosylation after Intravenous Delivery in C57BL/6J Mice

rAAVrh74.MCK.GALGT2 is a surrogate gene therapy that inhibits muscular dystrophy in multiple animal models. Here, we report on a dose-response study of functional muscle GALGT2 expression as well as toxicity and biodistribution studies after systemic intravenous (i.v.) delivery of rAAVrh74.MCK.GALGT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zygmunt, Deborah A., Xu, Rui, Jia, Ying, Ashbrook, Anna, Menke, Chelsea, Shao, Guohong, Yoon, Jung Hae, Hamilton, Sonia, Pisharath, Harshan, Bolon, Brad, Martin, Paul T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923506/ https://www.ncbi.nlm.nih.gov/pubmed/31890730 http://dx.doi.org/10.1016/j.omtm.2019.10.005

Ejemplares similares

An Isolated Limb Infusion Method Allows for Broad Distribution of rAAVrh74.MCK.GALGT2 to Leg Skeletal Muscles in the Rhesus Macaque
por: Xu, Rui, et al.
Publicado: (2018)

A first-in-human phase I/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2
por: Flanigan, Kevin M., et al.
Publicado: (2022)

Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength
por: Martin, Paul T., et al.
Publicado: (2021)

Evaluation of rAAVrh74 gene therapy vector seroprevalence by measurement of total binding antibodies in patients with Duchenne muscular dystrophy
por: Goedeker, Natalie L., et al.
Publicado: (2023)

Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial
por: Mendell, Jerry R., et al.
Publicado: (2020)

Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx Mouse Model of Duchenne Muscular Dystrophy
por: Potter, Rachael A., et al.
Publicado: (2021)

Assessment of rAAVrh.74.MHCK7.micro-dystrophin Gene Therapy Using Magnetic Resonance Imaging in Children With Duchenne Muscular Dystrophy
por: Willcocks, Rebecca J., et al.
Publicado: (2021)

Systemic delivery of AAVrh74.tMCK.hCAPN3 rescues the phenotype in a mouse model for LGMD2A/R1
por: Sahenk, Zarife, et al.
Publicado: (2021)

Pre Clinical Assessment of AAVrh74.MCK.GNE Viral Vector Therapeutic Potential: Robust Activity Despite Lack of Consistent Animal Model for GNE Myopathy
por: Mitrani-Rosenbaum, Stella, et al.
Publicado: (2022)

Therapeutic efficacy of rscAAVrh74.miniCMV.LIPA gene therapy in a mouse model of lysosomal acid lipase deficiency
por: Lam, Patricia, et al.
Publicado: (2022)

Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates
por: Borel, Florie, et al.
Publicado: (2016)

Development of capsid- and genome-modified optimized AAVrh74 vectors for muscle gene therapy
por: Shoti, Jakob, et al.
Publicado: (2023)

A role for Galgt1 in skeletal muscle regeneration
por: Singhal, Neha, et al.
Publicado: (2015)

The Viral Chemokine MCK-2 of Murine Cytomegalovirus Promotes Infection as Part of a gH/gL/MCK-2 Complex
por: Wagner, Felicia M., et al.
Publicado: (2013)

AAVrh10 Vector Corrects Disease Pathology in MPS IIIA Mice and Achieves Widespread Distribution of SGSH in Large Animal Brains
por: Hocquemiller, Michaël, et al.
Publicado: (2019)

AAVrh10 vector corrects pathology in animal models of GM1 gangliosidosis and achieves widespread distribution in the CNS of nonhuman primates
por: Hocquemiller, Michaël, et al.
Publicado: (2022)

Mck1 kinase is a new player in the DNA damage checkpoint pathway
por: Sanvisens Delgado, Nerea, et al.
Publicado: (2019)

Correction: Mck1 kinase is a new player in the DNA damage checkpoint pathway
Publicado: (2020)

The budding yeast GSK-3 homologue Mck1 is an essential component of the spindle position checkpoint
por: Rathi, Siddhi, et al.
Publicado: (2022)

The Yeast GSK-3 Homologue Mck1 Is a Key Controller of Quiescence Entry and Chronological Lifespan
por: Quan, Zhenzhen, et al.
Publicado: (2015)

The MAPKKK CgMck1 Is Required for Cell Wall Integrity, Appressorium Development, and Pathogenicity in Colletotrichum gloeosporioides
por: Fang, Yu-Lan, et al.
Publicado: (2018)

Mck1 defines a key S-phase checkpoint effector in response to various degrees of replication threats
por: Li, Xiaoli, et al.
Publicado: (2019)

Persistent Expression of Biologically Active Anti-HER2 Antibody by AAVrh.10-mediated Gene Transfer
por: Wang, Guoqing, et al.
Publicado: (2010)

Can early treatment of twitcher mice with high dose AAVrh10-GALC eliminate the need for BMT?
por: Rafi, Mohammad A, et al.
Publicado: (2021)

A Yeast GSK-3 Kinase Mck1 Promotes Cdc6 Degradation to Inhibit DNA Re-Replication
por: Ikui, Amy E., et al.
Publicado: (2012)

Chronological Lifespan in Yeast Is Dependent on the Accumulation of Storage Carbohydrates Mediated by Yak1, Mck1 and Rim15 Kinases
por: Cao, Lu, et al.
Publicado: (2016)

Mouse Cytomegalovirus Differentially Exploits Cell Surface Glycosaminoglycans in a Cell Type-Dependent and MCK-2-Independent Manner
por: Pontejo, Sergio M, et al.
Publicado: (2019)

Long-term muscle-specific overexpression of DOK7 in mice using AAV9-tMCK-DOK7
por: Huang, Yu-Ting, et al.
Publicado: (2023)

Intrathecal administration of IGF-I by AAVrh10 improves sensory and motor deficits in a mouse model of diabetic neuropathy
por: Homs, Judit, et al.
Publicado: (2014)

Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice
por: Tanguy, Yannick, et al.
Publicado: (2015)

Intra-CSF AAV9 and AAVrh10 Administration in Nonhuman Primates: Promising Routes and Vectors for Which Neurological Diseases?
por: Bey, Karim, et al.
Publicado: (2020)

Validation of Anti-Adeno Associated Virus Serotype rh10 (AAVrh.10) Total and Neutralizing Antibody Immunogenicity Assays
por: Butala-Flores, Elizabeth, et al.
Publicado: (2023)

Synthesis of Chiral MOF‐74 Frameworks by Post‐Synthetic Modification by Using an Amino Acid
por: Gheorghe, Andreea, et al.
Publicado: (2020)

MCK1 is a novel regulator of myo-inositol phosphate synthase (MIPS) that is required for inhibition of inositol synthesis by the mood stabilizer valproate
por: Yu, Wenxi, et al.
Publicado: (2017)

AAVrh.10-mediated Genetic Delivery of Bevacizumab to the Pleura to Provide Local Anti-VEGF to Suppress Growth of Metastatic Lung Tumors
por: Watanabe, Masaki, et al.
Publicado: (2010)

Erratum: The MAPKKK CgMck1 Is Required for Cell Wall Integrity, Appressorium Development, and Pathogenicity in Colletotrichum gloeosporioides (Genes 2018, 9, 543)
por: Fang, Yu-Lan, et al.
Publicado: (2019)

Selective transduction of cerebellar Purkinje and granule neurons using delivery of AAV-PHP.eB and AAVrh10 vectors at axonal terminal locations
por: Surdyka, Magdalena, et al.
Publicado: (2022)

Rational design of AAVrh10-vectored ACE2 functional domain to broadly block the cell entry of SARS-CoV-2 variants
por: Li, Minchao, et al.
Publicado: (2022)

Glycosylation alterations in serum of Alzheimer's disease patients show widespread changes in N‐glycosylation of proteins related to immune function, inflammation, and lipoprotein metabolism
por: Tena, Jennyfer, et al.
Publicado: (2022)

Comprehensive fitness maps of Hsp90 show widespread environmental dependence
por: Flynn, Julia M, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rrt0fu5ter0oe68uj6t6tkmf77